AWA
ZNTL icon

Acorn Wealth Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Acorn Wealth Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$27K – 279
2025
Q4 		$27K Hold
20,000
– – 0.01% 267
2025
Q3 		$30.2K Hold
20,000
– – 0.01% 280
2025
Q2 		$23.2K Buy
+20,000
New +$26.4K 0.01% 249

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Acorn Wealth Advisors's ZNTL Position: Q1 2026 in Review

Acorn Wealth Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2026, closing a stake of 20,000 shares — an estimated $27K sold.

Acorn Wealth Advisors first reported a position in ZNTL in Q2 2025 and held it in 3 quarters. The position peaked at $30.2K in Q3 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Acorn Wealth Advisors reported no remaining Zentalis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Acorn Wealth Advisors sold 20,000 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $27K.
  • Acorn Wealth Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Acorn Wealth Advisors's Zentalis Pharmaceuticals position peaked at $30.2K in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Acorn Wealth Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.